Beth E. Dunning

5.4k total citations · 1 hit paper
64 papers, 4.5k citations indexed

About

Beth E. Dunning is a scholar working on Surgery, Cellular and Molecular Neuroscience and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Beth E. Dunning has authored 64 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Surgery, 37 papers in Cellular and Molecular Neuroscience and 31 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Beth E. Dunning's work include Neuropeptides and Animal Physiology (35 papers), Diabetes Treatment and Management (25 papers) and Pancreatic function and diabetes (24 papers). Beth E. Dunning is often cited by papers focused on Neuropeptides and Animal Physiology (35 papers), Diabetes Treatment and Management (25 papers) and Pancreatic function and diabetes (24 papers). Beth E. Dunning collaborates with scholars based in United States, Sweden and Switzerland. Beth E. Dunning's co-authors include James E. Foley, Gerald J. Taborsky, Bo Åhrén, John E. Gerich, Anja Schweizer, Edwin B. Villhauer, Jens J. Holst, Andrea Mari, Richard C. Veith and Mary E. Russell and has published in prestigious journals such as Journal of Clinical Investigation, Endocrine Reviews and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Beth E. Dunning

64 papers receiving 4.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

1-[[(3-Hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: A Potent, Selective, and Orally Bioavailable Dipeptidyl Peptidase IV Inhibitor with Antihyperglycemic Properties

2003 519 citations Edwin B. Villhauer, J. A. Brinkman et al. Journal of Medicinal Chemistry profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Beth E. Dunning United States	34	2.9k	2.1k	1.7k	1.3k	885	64	4.5k
Raymond A. Pederson Canada	44	4.8k 1.6×	3.0k 1.4×	2.3k 1.4×	2.5k 2.0×	1.9k 2.1×	125	6.9k
John M. Amatruda United States	41	2.5k 0.8×	1.2k 0.6×	1.7k 1.0×	280 0.2×	497 0.6×	84	4.6k
Kyle W. Sloop United States	40	2.7k 0.9×	1.3k 0.6×	2.4k 1.4×	721 0.6×	173 0.2×	89	5.1k
Peter Proks United Kingdom	39	1.6k 0.6×	2.5k 1.2×	2.5k 1.5×	677 0.5×	93 0.1×	96	5.0k
Grzegorz Godlewski United States	33	1.1k 0.4×	874 0.4×	901 0.5×	770 0.6×	173 0.2×	68	3.8k
Atsuo Goto Japan	35	741 0.3×	319 0.2×	1.8k 1.1×	402 0.3×	160 0.2×	124	4.2k
Michael Tanen United States	14	886 0.3×	319 0.2×	972 0.6×	206 0.2×	313 0.4×	21	2.2k
U. Panten Germany	33	942 0.3×	1.7k 0.8×	1.8k 1.1×	522 0.4×	42 0.0×	105	3.4k
Gary J. Grover United States	36	925 0.3×	319 0.2×	1.7k 1.0×	428 0.3×	97 0.1×	104	4.6k
Edmund J. Sybertz United States	29	387 0.1×	629 0.3×	884 0.5×	304 0.2×	387 0.4×	93	3.4k

Countries citing papers authored by Beth E. Dunning

Since Specialization

Citations

This map shows the geographic impact of Beth E. Dunning's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Beth E. Dunning with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Beth E. Dunning more than expected).

Fields of papers citing papers by Beth E. Dunning

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Beth E. Dunning. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Beth E. Dunning. The network helps show where Beth E. Dunning may publish in the future.

Co-authorship network of co-authors of Beth E. Dunning

This figure shows the co-authorship network connecting the top 25 collaborators of Beth E. Dunning. A scholar is included among the top collaborators of Beth E. Dunning based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Beth E. Dunning. Beth E. Dunning is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Åhrén, Bo, Anja Schweizer, S. Dejager, et al.. (2011). Mechanisms of action of the dipeptidyl peptidase‐4 inhibitor vildagliptin in humans. Diabetes Obesity and Metabolism. 13(9). 775–783. 136 indexed citations

Åhrén, Bo, Anja Schweizer, S. Dejager, et al.. (2008). Vildagliptin improves alpha cell glucose sensing in patients with type 2 diabetes. Lund University Publications (Lund University). 6 indexed citations

Åhrén, Bo, et al.. (2008). Clinical Measures of Islet Function: Usefulness to Characterize Defects in Diabetes. Current Diabetes Reviews. 4(2). 129–145. 21 indexed citations

Vella, Adrian, Gerlies Bock, Paula D. Giesler, et al.. (2007). Effects of Dipeptidyl Peptidase-4 Inhibition on Gastrointestinal Function, Meal Appearance, and Glucose Metabolism in Type 2 Diabetes. Diabetes. 56(5). 1475–1480. 162 indexed citations

He, Yanling, Yibin Wang, Julie Bullock, et al.. (2007). Pharmacodynamics of Vildagliptin in Patients With Type 2 Diabetes During OGTT. The Journal of Clinical Pharmacology. 47(5). 633–641. 85 indexed citations

Mari, Andrea, William M. Sallas, Yanling He, et al.. (2005). Vildagliptin, a Dipeptidyl Peptidase-IV Inhibitor, Improves Model-Assessed β-Cell Function in Patients with Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. 90(8). 4888–4894. 324 indexed citations

Villhauer, Edwin B., J. A. Brinkman, Bryan F. Burkey, et al.. (2003). 1-[[(3-Hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: A Potent, Selective, and Orally Bioavailable Dipeptidyl Peptidase IV Inhibitor with Antihyperglycemic Properties. Journal of Medicinal Chemistry. 46(13). 2774–2789. 519 indexed citations breakdown →

Dunning, Beth E., Mary Courtney Moore, Tadasu Ikeda, et al.. (2002). Portal glucose infusion exerts an incretin effect associated with changes in pancreatic neural activity in conscious dogs. Metabolism. 51(10). 1324–1330. 13 indexed citations

Villhauer, Edwin B., J. A. Brinkman, Beth E. Dunning, et al.. (2002). 1-[2-[(5-Cyanopyridin-2-yl)amino]ethylamino]acetyl-2-(S)-pyrrolidinecarbonitrile: A Potent, Selective, and Orally Bioavailable Dipeptidyl Peptidase IV Inhibitor with Antihyperglycemic Properties. Journal of Medicinal Chemistry. 45(12). 2362–2365. 104 indexed citations

10.

Pratley, Richard E., James E. Foley, & Beth E. Dunning. (2001). Rapid Acting Insulinotropic Agents: Restoration of Early Insulin Secretion as a Physiologic Approach to Improve Glucose Control. Current Pharmaceutical Design. 7(14). 1375–1397. 30 indexed citations

11.

Hollander, Priscilla, et al.. (2000). Nateglinide, but not glyburide, selectively enhances early insulin release and more effectively controls post-meal glucose excursions with less total insulin exposure. Diabetes Research and Clinical Practice. 50. 70–71. 7 indexed citations

12.

Hu, Shiling, Shuya Wang, & Beth E. Dunning. (1999). Tissue Selectivity of Antidiabetic Agent Nateglinide: Study on Cardiovascular and β-Cell KATP Channels. Journal of Pharmacology and Experimental Therapeutics. 291(3). 1372–1379. 23 indexed citations

13.

Dunning, Beth E. & Bo Åhrén. (1992). Reduced Pancreatic Content of the Inhibitory Neurotransmitter Galanin in Genetically Obese, Hyperinsulinemic Mice. Pancreas. 7(2). 233–239. 6 indexed citations

14.

Åhrén, Bo, Gerhard Böttcher, Stephan Kowalyk, et al.. (1990). Galanin is co-localized with noradrenaline and neuropeptide Y in dog pancreas and celiac ganglion. Cell and Tissue Research. 261(1). 49–58. 66 indexed citations

15.

Lindskog, S., Beth E. Dunning, H. Mårtensson, et al.. (1990). Galanin of the homologous species inhibits insulin secretion in the rat and in the pig. Acta Physiologica Scandinavica. 139(4). 591–596. 32 indexed citations

16.

Dunning, Beth E. & Gerald J. Taborsky. (1989). Galanin release during pancreatic nerve stimulation is sufficient to influence islet function. American Journal of Physiology-Endocrinology and Metabolism. 256(1). E191–E198. 50 indexed citations

17.

Ahrén, Bo, Beth E. Dunning, Peter J. Havel, Richard C. Veith, & Gerald J. Taborsky. (1988). Extraction of epinephrine and norepinephrine by the dog pancreas in vivo. Metabolism. 37(1). 68–73. 17 indexed citations

18.

Dunning, Beth E. & Gerald J. Taborsky. (1988). Galanin—Sympathetic Neurotransmitter in Endocrine Pancreas?. Diabetes. 37(9). 1157–1162. 72 indexed citations

19.

Klaff, Leslie J., Beth E. Dunning, & Gerald J. Taborsky. (1988). Somatostatin-28 Does Not Regulate Islet Function in the Dog*. Endocrinology. 123(6). 2668–2674. 8 indexed citations

20.

Havel, Peter J., Richard C. Veith, Beth E. Dunning, & Gerald J. Taborsky. (1988). Pancreatic noradrenergic nerves are activated by neuroglucopenia but not by hypotension or hypoxia in the dog. Evidence for stress-specific and regionally selective activation of the sympathetic nervous system.. Journal of Clinical Investigation. 82(5). 1538–1545. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact